Influence of erythropoietin on immunological system of patients with chronic renal failure;Wpływ erytropoetyny na układ immunologiczny u chorych z przewlekła̧ niewydolnościa̧ nerek

Polski Merkuriusz Lekarski

Volumn 15, Issue 88, 2003, Pages 326-329

  Dȩbska Ślizień, Alicja ^a,c   Rutkowski, Bolesław ^a   Manitius, Jacek ^a   Zdrojewski, Zbigniew ^a   Szołkiewicz, Marek ^a   Bułło, Barbara ^a   Lizakowski, Sławomir ^a   Myśliwskai, Jolanta ^b   Myśliwski, Andrzej ^b   Bryl, Ewa ^b   Trzonkowski, Piotr ^b   Ba̧kowska, Alicja ^b   Rachoń, Dominik ^b   Wańkowicz, Zofia ^d   Grenda, Ryszard ^d   Klinger, Marian ^d   Wiȩcek, Andrezej ^d   Grzegorzewska, Alicja ^d   Sułowicz, Władysław ^d  

^a Katedra I Klinika Nefrologii   (Poland)

^b Zak ad Histologii   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d NONE

Author keywords

Chronic renal failure; Epoetin; Immune system

Indexed keywords

C REACTIVE PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; ERYTHROPOIETIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; BLOOD CULTURE; BLOOD LEVEL; CARBOHYDRATE METABOLISM; CELL VIABILITY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COGNITION; COLORIMETRY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOMODULATION; LIPID METABOLISM; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; NEPHELOMETRY; OXYGEN SUPPLY; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PHYSICAL ACTIVITY; PROTEIN METABOLISM; SEXUAL BEHAVIOR; T LYMPHOCYTE SUBPOPULATION;

EID: 10744223458     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Bryl E. i wsp.: Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of the hemodialysis patients. Artificial Organs, 1999, 23 (9), 809.
2. Bryl E. i wsp.: The influence of recombinant human erythropoietin on tumor necrosis factor and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artificial Organs, 1998, 22 (3), 177.
3. Dȩbska-Ślizień A. i wsp.: Stosowanie podskórne rekombinowanej ludzkiej erytropoetyny (r-Epo) w terapii niedokrwistości u chorych z przewlekła̧ niewydolnoś cia̧ nerek leczonych zachowawczo. Pol. Arch. Med. Wewn., 1991, 85, 334.
4. Kokot F. i wsp.: Influence of erythropoietin treatment on endocrine abnormalities in haemodialysed patients. Contrib. Nephrol., 1989, 76, 257.
5. Manitius J. i wsp.: Influence of 'nonhematological' doses of erythropoietin on lipid carbohydrate metabolism and life quality in hemodialysis patient. Nephron, 1995, 69, 363,
6. Pollock C.A. i wsp.: Effect of erythropoietin therapy on the lipid profile in end - stage renal failure. Kidney Int., 1994, 45, 897.
7. Viron B. i wsp.: Effect of recombinant Human erythropoietin on nutritional status and plasma lipids in uremic patients. Nephron, 1992, 60, 249.
8. Rutkowski B. i wsp.: The influence of erythropoietin on cytokines in haemodialysis patients. Nephrology, 1997, 3, 323.
9. Myśliwska J. i wsp.: Low doses of recombinant human erythropoietin raise serum interleukin-2 levels in hemodialysis patients. J. Nephrol., 1996, 9, 1, 30.
10. Trzonkowski P. i wsp.: Long-term therapy with recombinant human erythropoietin decreases percentage of CD 152+ lymphocytes in primary glomerulonephritis and haemodialysed patients. Nephrol. Dial. Transplant., 2002, 17, 1070.
11. Casadevall N. i wsp.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med., 2002, 346, 7, 469.
12. Bunn H.F.: Drug induced autoimmune red-cell aplasia. N. Engl. J. Med., 2002, 346, 7, 522.
13. Gershon S. i wsp.: Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med., 2002, 346, 20, 1584.
14. Wiȩcek A. i wsp.: Wpływ krótkotrwałego leczenia erytropoetyná na zachowanie siȩ wybranych parametrów odporności komórkowozależnej i humoralnej u hemodializowanych chorych na mocznicȩ. Pol. Arch. Med. Wewn., 1995, 93, 41.
15. Sułowicz W., Hanicki Z., Lisiewicz J.: Aktywnoṡċ wybranych enzyṁw neutrofilów chorych przewlekle dializowanych leczonych erytropoetyna̧ (rHuEPO). Pol. Arch. Med. Wewn., 1991, 85, 391.